ARQ 531

Drug Profile

ARQ 531

Alternative Names: ARQ531

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator ArQule
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Dec 2016 Interim pharmacodynamics data from a preclinical trial in Cancer presented at the 58th Annual Meeting of the American Society of Hematology (ASH–2016)
  • 07 Nov 2016 ArQule announces intention to submit IND to the US FDA in early 2017
  • 07 Nov 2016 ArQule plans a clinical trial for Chronic lymphocytic leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top